Bristol-Myers Squibb Zerit and Videx
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Black-box warnings and the "Warnings" and "Precautions" sections of labeling for Zerit (stavudine), Videx (didanosine) and Videx EC will be strengthened following reports of fatal lactic acidosis in the infants of pregnant women taking a combination of Videx and Zerit. "Fatal lactic acidosis has been reported in pregnant women who received the combination of didanosine and stavudine with other retroviral agents," the revised black-box warning says. "The combination of didanosine and stavudine should be used with caution during pregnancy and is recommended only if the potential benefit outweighs the risk
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.